Signal CRISPR Clinical Trials 2026: In Vivo Delivery as the Single Most Important Transition

Summary

Casgevy, an FDA-approved treatment for sickle cell disease and beta-thalassaemia, has been gaining broad approval across the United States, the European Union and the United Kingdom. CTX310 produced a single CRISPR-based dose that lowered ANGPTL3 levels and cut LDL by about 50 percent. Those results were reported in the New England Journal of Medicine in November 2025. Researchers point to in vivo delivery through lipid nanoparticles and viral vectors as the single most important technical transition underway. Late-stage trials have also opened targeting high cholesterol, inherited blindness, terminal cancer and rare genetic disease.